insights_auto
Why is AXGN up 2.61%?
Dive Deeperchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
$50.02
arrow_upward
+2.61%(+1.27) 1D
$50.00
arrow_downward
-0.04% (-0.020)bedtimeAfter hours
Closed: Nov 6, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
$48.55
High
$50.29
Low
$48.14
Mkt. cap
2.99B
Avg. vol.
1.79M
Volume
1.67M
52-wk high
$52.91
52-wk low
$23.00
EPS
-$0.68
Beta
1.21
Shares outstanding
59.73M
No. of employees
622
Open
$48.55
High
$50.29
Low
$48.14
Mkt. cap
2.99B
Avg. vol.
1.79M
Volume
1.67M
52-wk high
$52.91
52-wk low
$23.00
EPS
-$0.68
Beta
1.21
Shares outstanding
59.73M
No. of employees
622
News stories
From web sources and news partners
شبكة تواصل الإخبارية
·
19 minutes ago
Wall Street stocks rally after heavy AI-related selloff
www.tmgm.com
·
5 hours ago
United States CFTC S&P 500 NC Net Positions up to $-129.4K from previous $-134.4K
marketscreener.com
·
4 hours ago
S&P 500 Posts Weekly Drop as Energy, Technology Slide in Election Aftermath
TradingView
·
4 hours ago
Nasdaq rebounds after tech selloff but sheds 3% for the week
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Florida, United States
SectorHealth Care
IndustryMedical device
Websiteaxogeninc.com